Everolimus for social skills in PTEN gene changes
Part of Cancer, Genetic & congenital, Mental health clinical trials.
This trial tests if everolimus can improve social abilities in people with PTEN germline mutations who have social difficulties. It may help those with PTEN Hamartoma Tumor Syndrome by targeting a specific pathway in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed PTEN gene change (PTEN Hamartoma Tumor Syndrome).
- You have at least moderate social challenges, like trouble interacting with others.
- You speak English fluently.
- If you are a woman who could become pregnant, you must use birth control and not plan pregnancy during the study.
- You have a caregiver or family member who can help with reports and transportation.
- You are medically stable and can swallow pills.
- You are willing to not change your school, therapies, or services during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
This trial tests the combination of everolimus (a targeted pill) with a PD-1 immunotherapy drug for people with advanced colorectal cancer that has a specific gene change (PTEN mutation). The goal is to see if this two-drug approach works better than standard treatments for cancers that have stopped responding to chemotherapy.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
Hear when a new PTEN Hamartoma Tumor Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.